400 Participants Needed

Neurodevelopment for Huntington's Disease

(ChANGE HD Trial)

Recruiting at 5 trial locations
SK
SS
Overseen ByStudy Staff
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Peggy C Nopoulos
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how brain development might be affected in individuals with a genetic risk for Huntington's Disease (HD), a condition impacting thinking, emotions, and movement. Researchers aim to determine if brain changes occur long before any symptoms appear. Participants will undergo brain scans and various tests to assess brain structure and function. This trial is open to individuals aged 6 to 30 with a parent or grandparent with HD who are comfortable knowing their risk. Those with metal in their body or a history of major brain-related health issues are not eligible. As an unphased study, this trial offers a unique opportunity to contribute to understanding HD risk factors and potentially aid in early intervention strategies.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores the neurodevelopmental progression from childhood to adulthood in individuals with gene-expanded Huntington's disease. Unlike the standard treatments that mainly focus on managing symptoms in later stages, this study aims to understand early changes in the brain. By identifying these changes early on, scientists hope to uncover new intervention points and potentially develop more effective treatments targeting the root causes of the condition before significant symptoms appear. This approach could revolutionize how Huntington's disease is managed, shifting the focus from symptom control to prevention and early treatment.

Who Is on the Research Team?

PC

Peggy C Nopoulos, MD

Principal Investigator

University of Iowa

Are You a Good Fit for This Trial?

Inclusion Criteria

Family history of Huntington's Disease
Age 6-30 years
Age-appropriate knowledge of HD and personal risk

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Initial assessment of brain structure and function using MRI, cognitive tests, and behavioral assessments

1 day
1 visit (in-person)

Annual Follow-up

Participants undergo annual assessments of brain structure and function, including MRI, cognitive tests, and behavioral assessments

3-4 annual visits
3-4 visits (in-person)

Long-term Monitoring

Continued monitoring of brain development and function over several years

Long-term

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Peggy C Nopoulos

Lead Sponsor

Trials
2
Recruited
420+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security